 Leonard Seibold
Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glaucoma | 33 | 2023 | 202 | 7.600 |
Why?
| | Glaucoma, Open-Angle | 20 | 2023 | 95 | 6.760 |
Why?
| | Intraocular Pressure | 44 | 2023 | 276 | 6.440 |
Why?
| | Trabeculectomy | 15 | 2022 | 65 | 3.760 |
Why?
| | Phacoemulsification | 12 | 2023 | 107 | 3.730 |
Why?
| | Cataract | 10 | 2023 | 185 | 2.910 |
Why?
| | Ocular Hypertension | 7 | 2022 | 61 | 2.730 |
Why?
| | Glaucoma Drainage Implants | 9 | 2022 | 47 | 2.400 |
Why?
| | Tonometry, Ocular | 22 | 2022 | 83 | 2.060 |
Why?
| | Visual Acuity | 11 | 2022 | 274 | 1.880 |
Why?
| | Trabecular Meshwork | 7 | 2019 | 77 | 1.570 |
Why?
| | Glaucoma, Angle-Closure | 2 | 2020 | 16 | 1.310 |
Why?
| | Ophthalmology | 4 | 2023 | 77 | 1.160 |
Why?
| | Cataract Extraction | 5 | 2020 | 76 | 1.150 |
Why?
| | Laser Therapy | 3 | 2018 | 100 | 1.140 |
Why?
| | Ophthalmic Solutions | 6 | 2018 | 66 | 0.910 |
Why?
| | Antihypertensive Agents | 5 | 2017 | 429 | 0.890 |
Why?
| | Filtering Surgery | 6 | 2016 | 22 | 0.880 |
Why?
| | Lens Implantation, Intraocular | 3 | 2018 | 57 | 0.850 |
Why?
| | Perception | 3 | 2021 | 311 | 0.750 |
Why?
| | Nerve Fibers | 2 | 2012 | 87 | 0.750 |
Why?
| | Retinal Ganglion Cells | 2 | 2012 | 92 | 0.730 |
Why?
| | Tomography, Optical Coherence | 2 | 2012 | 130 | 0.720 |
Why?
| | Stents | 4 | 2021 | 475 | 0.690 |
Why?
| | Laser Coagulation | 3 | 2023 | 54 | 0.670 |
Why?
| | Legislation, Drug | 1 | 2020 | 78 | 0.660 |
Why?
| | Specialization | 1 | 2020 | 115 | 0.660 |
Why?
| | Remote Sensing Technology | 1 | 2019 | 11 | 0.640 |
Why?
| | Pilocarpine | 1 | 2018 | 7 | 0.630 |
Why?
| | Ciliary Body | 2 | 2018 | 33 | 0.630 |
Why?
| | Medical Marijuana | 1 | 2020 | 97 | 0.620 |
Why?
| | Angiogenesis Inhibitors | 5 | 2020 | 214 | 0.590 |
Why?
| | Prospective Studies | 11 | 2021 | 6220 | 0.580 |
Why?
| | Marijuana Use | 1 | 2020 | 167 | 0.570 |
Why?
| | Brimonidine Tartrate | 1 | 2017 | 9 | 0.560 |
Why?
| | Thiazines | 1 | 2017 | 9 | 0.560 |
Why?
| | Retrospective Studies | 21 | 2023 | 12550 | 0.560 |
Why?
| | Humans | 60 | 2023 | 114686 | 0.560 |
Why?
| | Timolol | 1 | 2017 | 14 | 0.560 |
Why?
| | Burnout, Professional | 1 | 2022 | 322 | 0.550 |
Why?
| | Marijuana Smoking | 1 | 2020 | 224 | 0.550 |
Why?
| | Sulfonamides | 2 | 2017 | 445 | 0.540 |
Why?
| | Preservatives, Pharmaceutical | 2 | 2013 | 24 | 0.540 |
Why?
| | Endoscopy | 2 | 2018 | 246 | 0.530 |
Why?
| | Circadian Rhythm | 2 | 2023 | 354 | 0.530 |
Why?
| | Corneal Diseases | 1 | 2016 | 33 | 0.520 |
Why?
| | Endophthalmitis | 1 | 2016 | 25 | 0.510 |
Why?
| | Aged, 80 and over | 12 | 2019 | 6347 | 0.510 |
Why?
| | Aged | 18 | 2021 | 19074 | 0.490 |
Why?
| | Physicians | 1 | 2022 | 772 | 0.450 |
Why?
| | Antibodies, Monoclonal | 1 | 2020 | 1262 | 0.450 |
Why?
| | Ocular Hypotension | 3 | 2022 | 10 | 0.450 |
Why?
| | Cloprostenol | 1 | 2013 | 13 | 0.450 |
Why?
| | Postoperative Period | 6 | 2019 | 289 | 0.440 |
Why?
| | Prosthesis Implantation | 4 | 2022 | 138 | 0.440 |
Why?
| | Middle Aged | 18 | 2020 | 26737 | 0.420 |
Why?
| | Drug Combinations | 3 | 2020 | 287 | 0.420 |
Why?
| | Benzalkonium Compounds | 1 | 2012 | 14 | 0.410 |
Why?
| | Wound Healing | 2 | 2012 | 258 | 0.370 |
Why?
| | Blood Pressure | 2 | 2017 | 1538 | 0.370 |
Why?
| | Adipocytes | 1 | 2012 | 188 | 0.370 |
Why?
| | Female | 25 | 2023 | 59507 | 0.370 |
Why?
| | Male | 24 | 2021 | 55596 | 0.370 |
Why?
| | Optic Disk | 1 | 2010 | 38 | 0.350 |
Why?
| | Stainless Steel | 1 | 2010 | 21 | 0.350 |
Why?
| | Uveitis | 2 | 2022 | 115 | 0.340 |
Why?
| | Contact Lenses | 2 | 2020 | 7 | 0.340 |
Why?
| | Antineoplastic Agents | 1 | 2020 | 1879 | 0.330 |
Why?
| | Software | 1 | 2012 | 530 | 0.310 |
Why?
| | Prednisolone | 2 | 2020 | 75 | 0.300 |
Why?
| | Treatment Outcome | 12 | 2022 | 9088 | 0.300 |
Why?
| | Minimally Invasive Surgical Procedures | 3 | 2019 | 154 | 0.280 |
Why?
| | Vision Disorders | 2 | 2020 | 130 | 0.280 |
Why?
| | Cross-Sectional Studies | 5 | 2022 | 4409 | 0.260 |
Why?
| | Sleep | 2 | 2023 | 631 | 0.260 |
Why?
| | Alkylating Agents | 2 | 2016 | 27 | 0.230 |
Why?
| | Glaucoma, Neovascular | 2 | 2015 | 10 | 0.230 |
Why?
| | Reproducibility of Results | 3 | 2021 | 2764 | 0.230 |
Why?
| | Glucocorticoids | 2 | 2020 | 532 | 0.230 |
Why?
| | Macular Edema | 1 | 2023 | 34 | 0.210 |
Why?
| | Adult | 13 | 2020 | 30550 | 0.200 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2023 | 79 | 0.200 |
Why?
| | Communication Barriers | 1 | 2023 | 89 | 0.200 |
Why?
| | Heart Rate | 2 | 2017 | 709 | 0.190 |
Why?
| | Diabetic Retinopathy | 1 | 2023 | 149 | 0.190 |
Why?
| | Manometry | 1 | 2021 | 89 | 0.180 |
Why?
| | Follow-Up Studies | 5 | 2022 | 4411 | 0.180 |
Why?
| | Health Status Disparities | 1 | 2023 | 200 | 0.180 |
Why?
| | Cyclopentolate | 1 | 2020 | 3 | 0.180 |
Why?
| | Microscopy, Acoustic | 1 | 2020 | 8 | 0.180 |
Why?
| | Gonioscopy | 1 | 2020 | 6 | 0.180 |
Why?
| | Administration, Ophthalmic | 1 | 2020 | 14 | 0.180 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.180 |
Why?
| | Vascular Endothelial Growth Factor A | 4 | 2020 | 498 | 0.180 |
Why?
| | Muscarinic Antagonists | 1 | 2020 | 25 | 0.180 |
Why?
| | Language | 1 | 2023 | 263 | 0.180 |
Why?
| | Magnetic Resonance Imaging | 2 | 2014 | 3052 | 0.180 |
Why?
| | Amyloidosis | 1 | 2020 | 36 | 0.180 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2020 | 36 | 0.170 |
Why?
| | Visual Fields | 1 | 2020 | 77 | 0.170 |
Why?
| | Surveys and Questionnaires | 3 | 2022 | 4623 | 0.170 |
Why?
| | Retinal Diseases | 1 | 2020 | 76 | 0.170 |
Why?
| | Eye Diseases | 1 | 2020 | 76 | 0.170 |
Why?
| | Infusions, Intravenous | 1 | 2020 | 371 | 0.160 |
Why?
| | Intraoperative Complications | 1 | 2020 | 122 | 0.160 |
Why?
| | Biosensing Techniques | 1 | 2020 | 100 | 0.160 |
Why?
| | Preoperative Period | 1 | 2019 | 103 | 0.160 |
Why?
| | Mitomycin | 2 | 2016 | 27 | 0.160 |
Why?
| | United States | 4 | 2023 | 12183 | 0.150 |
Why?
| | Time Factors | 2 | 2019 | 6115 | 0.150 |
Why?
| | Axial Length, Eye | 1 | 2018 | 9 | 0.150 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 14 | 0.150 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.150 |
Why?
| | Pseudophakia | 1 | 2018 | 11 | 0.150 |
Why?
| | Uveitis, Anterior | 1 | 2018 | 11 | 0.150 |
Why?
| | Young Adult | 5 | 2019 | 10469 | 0.150 |
Why?
| | Refraction, Ocular | 1 | 2018 | 30 | 0.150 |
Why?
| | Healthcare Disparities | 1 | 2023 | 480 | 0.140 |
Why?
| | Intravitreal Injections | 4 | 2020 | 45 | 0.140 |
Why?
| | Adrenergic alpha-1 Receptor Antagonists | 1 | 2016 | 18 | 0.140 |
Why?
| | Equipment Design | 1 | 2018 | 508 | 0.130 |
Why?
| | Drug Delivery Systems | 1 | 2019 | 296 | 0.130 |
Why?
| | Coronary Artery Disease | 1 | 2022 | 607 | 0.130 |
Why?
| | Fluoroquinolones | 1 | 2016 | 41 | 0.130 |
Why?
| | Lasers, Semiconductor | 1 | 2015 | 11 | 0.120 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 103 | 0.120 |
Why?
| | Drug Packaging | 1 | 2015 | 42 | 0.120 |
Why?
| | Device Removal | 1 | 2016 | 126 | 0.120 |
Why?
| | ACTH-Secreting Pituitary Adenoma | 1 | 2014 | 6 | 0.120 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2014 | 57 | 0.110 |
Why?
| | Orbital Neoplasms | 1 | 2014 | 21 | 0.110 |
Why?
| | Patient Preference | 1 | 2016 | 167 | 0.110 |
Why?
| | Travoprost | 1 | 2013 | 13 | 0.110 |
Why?
| | Antimetabolites | 1 | 2012 | 21 | 0.100 |
Why?
| | Telemedicine | 1 | 2021 | 662 | 0.100 |
Why?
| | Recombinant Fusion Proteins | 1 | 2015 | 616 | 0.100 |
Why?
| | Anterior Chamber | 1 | 2012 | 19 | 0.100 |
Why?
| | Adenoma | 1 | 2014 | 189 | 0.100 |
Why?
| | Conjunctiva | 1 | 2012 | 51 | 0.100 |
Why?
| | Blister | 1 | 2012 | 43 | 0.100 |
Why?
| | Prostaglandins F | 1 | 2011 | 17 | 0.100 |
Why?
| | Electromagnetic Fields | 1 | 2010 | 21 | 0.090 |
Why?
| | Medication Adherence | 1 | 2015 | 536 | 0.090 |
Why?
| | Tissue Donors | 1 | 2012 | 316 | 0.090 |
Why?
| | Equipment Safety | 1 | 2010 | 39 | 0.090 |
Why?
| | Torque | 1 | 2010 | 66 | 0.090 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2096 | 0.090 |
Why?
| | Dexamethasone | 1 | 2012 | 317 | 0.090 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 951 | 0.080 |
Why?
| | Cell Survival | 1 | 2012 | 1021 | 0.080 |
Why?
| | Reference Values | 1 | 2010 | 743 | 0.080 |
Why?
| | Cohort Studies | 1 | 2019 | 4895 | 0.080 |
Why?
| | Adolescent | 4 | 2020 | 17844 | 0.080 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 646 | 0.080 |
Why?
| | Inflammation | 1 | 2018 | 2480 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2016 | 1481 | 0.070 |
Why?
| | Cell Proliferation | 1 | 2012 | 2187 | 0.060 |
Why?
| | Administration, Topical | 2 | 2016 | 138 | 0.060 |
Why?
| | Cells, Cultured | 1 | 2012 | 3886 | 0.060 |
Why?
| | Safety-net Providers | 1 | 2023 | 95 | 0.050 |
Why?
| | Rabbits | 2 | 2012 | 733 | 0.040 |
Why?
| | Postoperative Complications | 2 | 2021 | 2128 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2022 | 304 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 478 | 0.040 |
Why?
| | Attitude | 1 | 2021 | 229 | 0.040 |
Why?
| | Risk Assessment | 2 | 2020 | 2968 | 0.040 |
Why?
| | Reoperation | 1 | 2020 | 514 | 0.040 |
Why?
| | Perioperative Care | 1 | 2019 | 127 | 0.040 |
Why?
| | Histological Techniques | 1 | 2018 | 40 | 0.040 |
Why?
| | Microscopy | 1 | 2018 | 125 | 0.040 |
Why?
| | Pharmaceutical Preparations | 1 | 2019 | 165 | 0.030 |
Why?
| | Fibrosis | 1 | 2018 | 453 | 0.030 |
Why?
| | Medication Errors | 1 | 2015 | 88 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2016 | 249 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1373 | 0.030 |
Why?
| | Disease Progression | 1 | 2020 | 2380 | 0.030 |
Why?
| | Iris | 1 | 2013 | 19 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1317 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2014 | 442 | 0.030 |
Why?
| | Prognosis | 1 | 2020 | 3329 | 0.030 |
Why?
| | Goblet Cells | 1 | 2012 | 16 | 0.030 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 281 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2012 | 159 | 0.020 |
Why?
| | Postoperative Care | 1 | 2012 | 222 | 0.020 |
Why?
| | Collagen | 1 | 2012 | 415 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 1842 | 0.020 |
Why?
| | Animals | 3 | 2012 | 31706 | 0.020 |
Why?
| | Child | 1 | 2020 | 18414 | 0.010 |
Why?
|
|
Seibold's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|